Articles liés à Drug Discovery and Development for Advanced Melanoma:...

Drug Discovery and Development for Advanced Melanoma: From lead compounds identification, optimization to in vivo anti-melanoma efficacy testing on animal models - Couverture souple

Wang, Zhao

 
9783846520703: Drug Discovery and Development for Advanced Melanoma: From lead compounds identification, optimization to in vivo anti-melanoma efficacy testing on animal models
Couverture souple
ISBN 10 : 3846520705 ISBN 13 : 9783846520703
Editeur : LAP LAMBERT Academic Publishing, 2011

Synopsis

Malignant melanoma is the most dangerous type of skin cancer. It accounts for about 75% of skin cancer deaths. Patients with advanced melanoma with dissemination to distant sites and visceral organs have a very poor prognosis, with a median survival time of 6 months and a 5-year survival rate of less than 5%. Over the past 40 years, no one drug or combination of drugs demonstrated any improvement on survival of metastatic melanoma patient. In the year 2011, FDA approved ipilimumab and Vemurafenib for the treatment of advanced melanoma. But both drugs only prolonged patients’ life of 2-3 months. So the war to fight advanced melanoma is far from ending. In this book, the author and colleagues used classical approaches discovering and developing novel therapeutic agents for advanced melanoma. They identified several new classes of compounds which showed very potent in vitro activity against metastatic melanoma cells and in vivo activity on several animal models. They further optimized the lead compounds activity through a knowledge-based molecule design. They also identified the cellular target of these compounds and elucidated their mechanism of action in killing melanoma cells.

Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.

Présentation de l'éditeur

Malignant melanoma is the most dangerous type of skin cancer. It accounts for about 75% of skin cancer deaths. Patients with advanced melanoma with dissemination to distant sites and visceral organs have a very poor prognosis, with a median survival time of 6 months and a 5-year survival rate of less than 5%. Over the past 40 years, no one drug or combination of drugs demonstrated any improvement on survival of metastatic melanoma patient. In the year 2011, FDA approved ipilimumab and Vemurafenib for the treatment of advanced melanoma. But both drugs only prolonged patients’ life of 2-3 months. So the war to fight advanced melanoma is far from ending. In this book, the author and colleagues used classical approaches discovering and developing novel therapeutic agents for advanced melanoma. They identified several new classes of compounds which showed very potent in vitro activity against metastatic melanoma cells and in vivo activity on several animal models. They further optimized the lead compounds activity through a knowledge-based molecule design. They also identified the cellular target of these compounds and elucidated their mechanism of action in killing melanoma cells.

Biographie de l'auteur

Zhao Wang, born in 1975, received his Bachelor of Medicine degree from the Shandong University in 2000. He received his Master of Pharmaceutical Sciences degree from the Peking Union Medical College (PUMC) in 2003. In 2010, he received his Ph.D. in Pharmaceutical Sciences from the University of Tennessee under the supervision of Prof. Wei Li.

Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.

Éditeur
LAP LAMBERT Academic Publishing
Date d'édition
2011
Langue
anglais
ISBN 10 
3846520705
ISBN 13 
9783846520703
Reliure
Broché
Nombre de pages
188
Coordonnées du fabricant
non disponible
Personne responsable
KreGa Onlinehandel GmbH
4950000000000
info@krega-onlinehandel.de

Birkenweg 31
Brakel
33034
Allemagne